Key Highlights
- The FDA review target date for resubmitted relacorilant in hypercortisolism is December 17, 2026, after a Complete Response Letter on December 30, 2025 and a resubmission on June 17, 2026.
- Lifyorli, which pairs relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer, won FDA approval in March 2026 and has been sold in the United States since April 2026, expanding the company beyond hypercortisolism.
- The CATALYST study found hypercortisolism in 23.8% of 1,057 patients with difficult-to-control type 2 diabetes, and Korlym cut HbA1c by 1.47% against 0.15% for placebo.
- The MOMENTUM trial found hypercortisolism in 27.3% of 1,086 patients with resistant hypertension, with results presented in March 2026.
Second Chance for Relacorilant After a Complete Response Letter
Corcept Therapeutics (NASDAQ:CORT) filed its Quarterly Report on November 3, 2026 for the period ended September 30. The commercial-stage company has sold Korlym for hypercortisolism, also called Cushing's syndrome, since 2012 and added an authorized generic in June 2024. It submitted a new drug application for relacorilant in December 2024, but the FDA issued a Complete Response Letter on December 30, 2025, saying more evidence of efficacy was needed even though it acknowledged the pivotal GRACE trial met its primary endpoint. After an April 2026 meeting, the company resubmitted on June 17, 2026, and the FDA review target is December 17, 2026. GRACE enrolled 152 patients for 22 weeks of open-label treatment, followed by a 12-week randomized Withdrawal phase for those who improved.
Why a Global Statistical Test Matters
Rather than demanding a new trial, the FDA asked for a global statistical test on data already submitted. This technique asks whether a drug moved a set of measures together, here hypertension, hyperglycemia and excess body weight, which suits a rare disease where symptoms differ by patient. The company says the outcome was positive. In GRACE's open-label phase, patients with hypertension saw mean systolic pressure fall 7.9 mm Hg and diastolic 5.4 mm Hg at 22 weeks, and 63% met the response criteria. In GRACE, patients on placebo after randomized withdrawal were more likely to lose blood pressure control (odds ratio 0.17, p-value 0.02). In the confirmatory GRADIENT trial of 137 patients, the blood pressure comparison with placebo was not statistically significant, though glucose and weight measures improved against placebo.
Lifyorli Launch, Safety Pitch and Approval Risks
Relacorilant does not bind the progesterone receptor, so the company says it avoids Korlym's endometrial effects, and it does not raise cortisol enough to cause the low potassium seen in 44% of patients in Korlym's pivotal trial. Cash, Revenue and Earnings figures were not in the supplied filing extract, so this article cannot assess financial results. Risks are concrete: the FDA could issue another Complete Response Letter, the GRADIENT blood pressure result was not significant, and the company is still building its cancer launch for Lifyorli, sold only since April 2026.
Where Things Stand
Possibly, but nothing is assured. The record gives Corcept Therapeutics (NASDAQ:CORT) a clearer path than a year ago, because the FDA itself requested the analysis the company supplied and set a December 17, 2026 target date. Against that, the earlier rejection shows the agency questioned efficacy, and GRADIENT did not show a significant blood pressure advantage. The key dates are December 17, 2026 for the hypercortisolism decision and early sales trends for Lifyorli in ovarian cancer.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...